Sign up
Pharma Capital

Express Scripts' stock soars on US$54bn CIGNA takeover deal

“Cigna’s acquisition of Express Scripts brings together two complementary customer-centric services companies, well-positioned to drive greater quality and affordability for customers”
deal agreed, hand shake
Express Scripts stock rose 17.4%

Express Scripts Holding Co (NASDAQ:ESRX) stock was up sharply in Thursday’s premarket deals after Cigna Corporation (NYSE:CI) said it is buying its rival health insurance company in a US$54bn transaction.

The takeover offer comprises US$48.75 per share in cash, as well as stock, equivalent to 0.2434 Cigna shares for every Express Scripts share - representing a 31% premium to the Express Scripts price before the deal was announced.

READ: Express Scripts to cap diabetes drugs spending costs for patients

David Cordani, Cigna chief executive, in a statement, said: “Cigna’s acquisition of Express Scripts brings together two complementary customer-centric services companies, well-positioned to drive greater quality and affordability for customers.”

He added: “This combination accelerates Cigna’s enterprise mission of improving the health, well-being and sense of security of those we serve, and in turn, expanding the breadth of services for our customers, partners, clients, health plans and communities.

“Together, we will create an expanded portfolio of health services, delivering greater consumer choice, closer alignment between the customer and health care provider, and more personalized value.”

Meanwhile, Express Scripts chief executive Tim Wentworth told investors that the combination “delivers attractive value” to his shareholders.

"Together, our two organizations will help make the healthiest choices the easiest choices, putting health and pharmacy services within reach of everyone we serve,” Wentworth said.

“Adding our company's leadership in pharmacy and medical benefit management, technology-powered clinical solutions, and specialized patient care model to Cigna’s track record of delivering value through innovation, we are positioned to transform healthcare.”

Express Scripts stock rose US$12.78 or 17.4% to trade at US$73.42 ahead of Thursday’s open, whereas Cigna was down US$9.50 or 4.89% at US$183.50.



Register here to be notified of future ESRX Company articles
View full ESRX profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.